MX2018006789A - Receptores quimericos modificados y composiciones y metodos relacionados. - Google Patents

Receptores quimericos modificados y composiciones y metodos relacionados.

Info

Publication number
MX2018006789A
MX2018006789A MX2018006789A MX2018006789A MX2018006789A MX 2018006789 A MX2018006789 A MX 2018006789A MX 2018006789 A MX2018006789 A MX 2018006789A MX 2018006789 A MX2018006789 A MX 2018006789A MX 2018006789 A MX2018006789 A MX 2018006789A
Authority
MX
Mexico
Prior art keywords
cells
methods
chimeric receptors
chimeric
receptors
Prior art date
Application number
MX2018006789A
Other languages
English (en)
Spanish (es)
Inventor
James Thompson Lucas
Brahmandam Archana
F Dubose Robert
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of MX2018006789A publication Critical patent/MX2018006789A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2018006789A 2015-12-03 2016-12-02 Receptores quimericos modificados y composiciones y metodos relacionados. MX2018006789A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262911P 2015-12-03 2015-12-03
US201662348130P 2016-06-09 2016-06-09
PCT/US2016/064861 WO2017096329A1 (en) 2015-12-03 2016-12-02 Modified chimeric receptors and related compositions and methods

Publications (1)

Publication Number Publication Date
MX2018006789A true MX2018006789A (es) 2019-02-13

Family

ID=57851322

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006789A MX2018006789A (es) 2015-12-03 2016-12-02 Receptores quimericos modificados y composiciones y metodos relacionados.

Country Status (10)

Country Link
US (1) US12139526B2 (enExample)
EP (2) EP4212547A1 (enExample)
JP (2) JP7184645B2 (enExample)
CN (2) CN108884140B (enExample)
AU (1) AU2016363025B2 (enExample)
CA (1) CA3007262A1 (enExample)
ES (1) ES2940607T3 (enExample)
MA (1) MA43380A (enExample)
MX (1) MX2018006789A (enExample)
WO (1) WO2017096329A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606970UA (en) 2012-02-23 2016-10-28 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
KR102714469B1 (ko) 2014-04-16 2024-10-11 주노 테라퓨틱스 게엠베하 세포 집단의 증대를 위한 방법, 키트 및 장치
MX382541B (es) 2014-04-23 2025-03-13 Juno Therapeutics Inc Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva.
SG11201609118RA (en) 2014-05-15 2016-11-29 Univ Singapore Modified natural killer cells and uses thereof
US11266739B2 (en) 2014-12-03 2022-03-08 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
WO2016100233A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP3240805B1 (en) 2014-12-15 2024-11-27 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
AU2016235388B2 (en) * 2015-03-20 2022-02-03 Children's National Medical Center Generating virus or other antigen-specific T cells from a naive T cell population
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
KR20190057308A (ko) 2016-09-02 2019-05-28 더 리전츠 오브 더 유니버시티 오브 캘리포니아 인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물
US20200165342A1 (en) * 2017-02-21 2020-05-28 Eutilex Co., Ltd. Hla-dr car-t compositions and methods of making and using the same
CN110636851B (zh) 2017-03-27 2023-11-03 新加坡国立大学 截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途
RU2019128544A (ru) 2017-03-27 2021-04-28 Нэшнл Юниверсити Оф Сингапур Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
ES3038614T3 (en) 2017-04-27 2025-10-14 Juno Therapeutics Inc Oligomeric particle reagents and methods of use thereof
EP3658163A4 (en) * 2017-07-25 2021-08-04 Board Of Regents, The University Of Texas System IMPROVED ANTIGENIC CHEMICAL RECEPTORS AND THEIR USES
WO2019079249A1 (en) * 2017-10-16 2019-04-25 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY
EP4512823A3 (en) 2017-11-01 2025-05-14 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
DK3703750T3 (da) 2017-11-01 2025-02-10 Juno Therapeutics Inc Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
CA3089170A1 (en) 2018-02-09 2019-08-15 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CA3103610A1 (en) * 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
MX2021001523A (es) * 2018-08-09 2021-05-27 Juno Therapeutics Inc Procesos para generar células modificadas y composiciones de las mismas.
CA3109209A1 (en) 2018-08-10 2020-02-13 Eutilex Co., Ltd. Chimeric antigen receptor that binds hla-dr and car-t cell
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
BR112021019722A2 (pt) 2019-04-09 2021-12-14 Nurix Therapeutics Inc Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico
US11530229B2 (en) 2019-05-17 2022-12-20 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
CN114364670B (zh) 2019-06-26 2025-06-13 纽力克斯治疗公司 用于Cbl-b抑制的取代苄基-三唑类化合物及其进一步用途
JP2022541320A (ja) * 2019-07-24 2022-09-22 エウレカ セラピューティクス インコーポレイテッド キメラ抗原受容体ｔ細胞及びその使用
CA3148769A1 (en) 2019-07-30 2021-02-04 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
BR112022001702A2 (pt) * 2019-07-30 2022-06-21 Univ Health Network Moléculas mhc classe ii e métodos de uso das mesmas
JP7439279B2 (ja) * 2020-02-13 2024-02-27 イミュノファーム テクノロジー カンパニー リミテッド キメラ抗原受容体の最適化

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
EP0787147A1 (en) 1994-10-25 1997-08-06 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2001043695A2 (en) 1999-10-27 2001-06-21 Cel-Sci Corporation Peptide constructs for treating autoimmune and related diseases
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
DE60134862D1 (de) 2000-08-21 2008-08-28 Apitope Technology Bristol Ltd Tolerogenische Peptide
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20040138116A1 (en) 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20070264229A1 (en) 2004-09-13 2007-11-15 Strominger Jack L Peptides for Treatment of Autoimmune Disease
US7691587B2 (en) 2006-06-01 2010-04-06 Allergan, Inc. Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin B peptides
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
US8747290B2 (en) 2007-12-07 2014-06-10 Miltenyi Biotec Gmbh Centrifuge for separating a sample into at least two components
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
PL3006459T3 (pl) 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
US8679492B2 (en) 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
WO2010151341A1 (en) 2009-06-24 2010-12-29 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
EP2601521B1 (en) 2010-08-06 2018-05-02 Ludwig-Maximilians-Universität München Identification of t cell target antigens
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012083069A2 (en) 2010-12-15 2012-06-21 The Board Of Trustees Of The Leland Stanford Junior University Measurement and monitoring of cell clonality
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
EP2694553B1 (en) 2011-04-01 2017-10-11 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
WO2012150495A1 (en) 2011-05-05 2012-11-08 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
EP2776451B1 (en) 2011-11-11 2018-07-18 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
US9447194B2 (en) 2012-02-13 2016-09-20 Seattle Children's Hospital Bispecific chimeric antigen receptors and encoding polynucleotides thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2833913A1 (en) 2012-04-02 2015-02-11 University Of Bristol Tolerisation- inducing composition
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
ES2786263T3 (es) 2012-07-13 2020-10-09 Univ Pennsylvania Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
MX380109B (es) 2012-08-20 2025-03-12 Fred Hutchinson Cancer Center Star Metodo y composiciones para inmunoterapia celular.
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
ES2784638T3 (es) 2014-03-04 2020-09-29 Merck Patent Gmbh Purificación de anticuerpos robusta
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
EP3149031B1 (en) 2014-05-29 2019-12-18 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-human papillomavirus 16 e7 t cell receptors
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
BR112017008693A2 (pt) 2014-10-31 2018-02-27 The Trustees Of The University Of Pennsylvania célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição.
US11266739B2 (en) 2014-12-03 2022-03-08 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
SG11201707540QA (en) 2015-03-16 2017-10-30 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
CN104910279B (zh) 2015-06-05 2019-02-22 重庆精准生物技术有限公司 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用
EP3156067A1 (en) 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
MA43378A (fr) 2015-12-03 2018-10-10 Juno Therapeutics Inc Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
BR112018011089A2 (pt) 2015-12-04 2018-12-04 Intellia Therapeutics Inc composições e métodos para a imuno-oncologia
CA3037086A1 (en) 2016-10-03 2018-04-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
AU2018345539A1 (en) 2017-10-03 2020-04-16 Editas Medicine, Inc. HPV-specific binding molecules

Also Published As

Publication number Publication date
MA43380A (fr) 2018-10-10
EP3383892B1 (en) 2022-12-21
CN116041538A (zh) 2023-05-02
AU2016363025B2 (en) 2021-04-08
CN108884140B (zh) 2022-10-25
US12139526B2 (en) 2024-11-12
CA3007262A1 (en) 2017-06-08
AU2016363025A1 (en) 2018-06-21
EP4212547A1 (en) 2023-07-19
CN108884140A (zh) 2018-11-23
US20180355014A1 (en) 2018-12-13
JP7184645B2 (ja) 2022-12-06
ES2940607T3 (es) 2023-05-09
EP3383892A1 (en) 2018-10-10
JP2019501647A (ja) 2019-01-24
JP2023022161A (ja) 2023-02-14
WO2017096329A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
MX2018006789A (es) Receptores quimericos modificados y composiciones y metodos relacionados.
MX2018005618A (es) Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
MX2017015239A (es) Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
MX2022005955A (es) Metodos y composiciones para terapia celular adoptiva.
CY1125196T1 (el) Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii
MX2024006992A (es) Anticuerpos contra ligando 1 de muerte programada.
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
CO7121348A2 (es) Proteínas de fusión de interleuquina-2 y usos de las mismas
CO2017000510A2 (es) Constructos de car
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
CO7151522A2 (es) Proteínas de fusión de interleuquina-10 y usos de las mismas
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
WO2015142675A3 (en) Treatment of cancer using chimeric antigen receptor
MX391279B (es) Anticuerpos biespecíficos contra cd3 y cd20.
MX382772B (es) Composición para usarse para prevenir o retardar el rechazo de trasplante de un tejido u órgano trasplantado en un sujeto.
MX370018B (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
BR112016013187A2 (pt) receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
MX2017002459A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
MX2017010159A (es) Vector que expresa conjuntamente vacunas y moléculas coestimuladoras.
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
MX377300B (es) Terapia con células madre en patologías endometriales.
EP4470623A3 (en) Nkt-cell subset for in vivo persistence and therapeutic activity and ppropagation of same